9.4. Analysis.
Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 4 Adverse events: 1. Continuous outcomes (skew).
| Adverse events: 1. Continuous outcomes (skew) | ||||
|---|---|---|---|---|
| Study | Intervention | Mean | SD | N |
| Change in BMI ‐ short term (skew) | ||||
| Covell 2012 | Risperidone depot | 1.29 | 1.9 | 23 |
| Covell 2012 | Typical depot antipsychotics | 0.48 | 1.4 | 26 |
| Change in BMI ‐ medium term (skew) | ||||
| Covell 2012 | Risperidone depot | 1.53 | 2.2 | 22 |
| Covell 2012 | Typical depot antipsychotics | 0.53 | 1.3 | 24 |
| Change in BMI ‐ long term (skew) | ||||
| Covell 2012 | Risperidone depot | 1.04 | 2.0 | 17 |
| Covell 2012 | Typical depot antipsychotics | ‐0.28 | 1.7 | 24 |
| Prolactin endpoint levels (ng/mL) ‐ short term (skew) | ||||
| Covell 2012 | Risperidone depot | 22.5 | 19.1 | 19 |
| Covell 2012 | Typical depot antipsychotics | 15.1 | 7.6 | 22 |
| Prolactin endpoint levels (ng/mL) ‐ medium term (skew) | ||||
| Covell 2012 | Risperidone depot | 23.4 | 13.8 | 18 |
| Covell 2012 | Typical depot antipsychotics | 16 | 7.5 | 21 |
| Prolactin endpoint levels (ng/mL) ‐ long term (skew) | ||||
| Covell 2012 | Risperidone depot | 19 | 10.6 | 14 |
| Covell 2012 | Typical depot antipsychotics | 15.2 | 5.1 | 18 |